ArticleAsia Oceania journal of nuclear medicine & biology2026
Utility of radioguided surgery in the intraoperative localization of neuroendocrine tumors: Report of 3 cases.
Article in Asia Oceania journal of nuclear medicine & biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patient selection rather than detection alone: Defining the surgical value of radioguided surgery in neuroendocrine tumors.Asia Oceania journal of nuclear medicine & biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine tumors (NETs) represent a heterogeneous group of neoplasms originating from neuroendocrine cells. Overexpression of somatostatin receptors is typically correlated with tumor differentiation. Localization and characterization of the primary tumor are essential, as radical surgery remains the treatment of choice for resectable disease. Additionally, identifying metastatic disease and assessing its extent are crucial for disease staging and monitoring response aimed at reducing total tumor volume. Radioguided surgery based on the ability to detect somatostatin receptor overexpression, is a valuable tool that aids in the identification of microscopic and occult endocrine tumors. In this context, we present three patients who achieved improved outcomes due to enhanced detection and identification of previously indeterminate or undetected lesions on prior imaging or even the detection of tumors that were not easily visualized without radioguided assistance. Complete tumor removal is a key prognostic factor in patients with NETs, improving quality of life and reducing the risk of tumor recurrence or locorregional metastasis. Achieving R0 or R1 resections has been associated with better survival outcomes. The successful implementation of radioguided surgery for NETs requires a multidisciplinary approach, both surgeons and nuclear medicine specialists playing a relevant role, and who must be aware of its prognostic significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.